Predicting metachronous liver metastasis from colorectal cancer using serum proteomic fingerprinting

Zhu, Dexiang; Zhong, Yun‐Shi; Wu, Haifu; Ye, Lechi; Wang, Jie; Li, Yan; Ye, Wei; Li, Ren; Xu, Bin; Xu, Jianmin; Qin, Xinyu

doi:10.1016/j.jss.2013.04.065

Cited by 13 publications

(7 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…RAD23B is involved in the nucleotide excision repair of damaged DNA, and its abnormal expression has been found in breast cancer 22 . GSPT2 is a GTPase that mediates translation termination and has been reported to be a biomarker for hepatocellular carcinoma and CRC liver metastasis in serum 23,24 . NDN is a member of the melanoma-associated antigen family and serves as a candidate tumor suppressor gene to facilitate the entry of the cell into cell cycle arrest in multiple tumors, including CRC 25 .…”

Section: Discussionmentioning

confidence: 99%

Noninvasive urinary protein signatures associated with colorectal cancer diagnosis and metastasis

Sun

Guo

Jing

et al. 2020

Preprint

View full text Add to dashboard Cite

Currently, imaging and serum carcinoembryonic antigen (CEA) tests are not sufficient for early detection and evaluation of metastasis and recurrence in colorectal cancer (CRC). To comprehensively discover and validate more accurate noninvasive biomarkers in urine, we adopted a staged discovery-verification-validation pipeline in 657 urine and 665 tissue samples from healthy controls and CRC patients with a distinct metastatic risk. The diagnostic signature generated combined with serum CEA levels revealed a significantly increased sensitivity (+34.8%) compared to CEA alone. Moreover, over 50% of CEA-negative metastatic patients were correctly predicted by the metastatic signature generated for metastatic risk. The tissue validation and functional study showed that CORO1C was associated with distant metastasis and enhanced the invasion and metastasis of CRC cells via a novel integrin/FAK/SRC and relevant pathways. Our findings provide novel urinary protein biomarkers and potential interventional targets to reliably detect CRC, especially in patients with metastatic CRC.

show abstract

Section: Discussionmentioning

confidence: 99%

Noninvasive urinary protein signatures associated with colorectal cancer diagnosis and metastasis

Sun

Guo

Jing

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…There are few studies focused on the proteomic profiles of CRLM patients [22] , [23] . These investigations are mainly related to predicting neoplastic recurrence after CRLM resection and metachronous liver metastasis from colorectal cancer in serum samples.…”

Section: Discussionmentioning

confidence: 99%

Metastatic Tissue Proteomic Profiling Predicts 5-Year Outcomes in Patients with Colorectal Liver Metastases

Marfà

Marti

Reyes

et al. 2016

Translational Oncology

View full text Add to dashboard Cite

Colorectal cancer (CRC) is one of the most common cancers in the developed countries, and nearly 70% of patients with CRC develop colorectal liver metastases (CRLMs). During the last decades, several scores have been proposed to predict recurrence after CRLM resection. However, these risk scoring systems do not accurately reflect the prognosis of these patients. Therefore, this investigation was designed to identify a proteomic profile in human hepatic tumor samples to classify patients with CRLM as “mild” or “severe” based on the 5-year survival. The study was performed on 85 CRLM tumor samples. Firstly, to evaluate any distinct tumor proteomic signatures between mild and severe CRLM patients, a training group of 57 CRLM tumor samples was characterized by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry, and a classification and regression tree (CART) analysis was subsequently performed. Finally, 28 CRLM tumor samples were used to confirm and validate the results obtained. Based on all the protein peaks detected in the training group, the CART analysis was generated, and four peaks were considered to be the most relevant to construct a diagnostic algorithm. Indeed, the multivariate model yielded a sensitivity of 85.7% and a specificity of 86.1%, respectively. In addition, the receiver operating characteristic (ROC) curve showed an excellent diagnostic accuracy to discriminate mild from severe CRLM patients (area under the ROC: 0.903). Finally, the validation process yielded a sensitivity and specificity of 68.8% and 83.3%, respectively. We identified a proteomic profile potentially useful to determine the prognosis of CRLM patients based on the 5-year survival.

show abstract

“…Zhu et al (73) used another approach, based on magnetic bead-based fractionation coupled with mass spectrometry, to compare serum samples from patients with metachronous liver metastases vs. patients without recurrence or metastases for at least 3 years after radical colorectal surgery. Serum proteomic fingerprinting was done, and it exhibited a promising value for predicting metachronous liver metastases in patients who underwent radical resection of colorectal cancer.…”

Section: Prognostic Biomarkersmentioning

confidence: 99%

“…Serum proteomic fingerprinting was done, and it exhibited a promising value for predicting metachronous liver metastases in patients who underwent radical resection of colorectal cancer. The peptides were recognized as fragments of alpha-fetoprotein, complement C4-A, fibrinogen alpha, eukaryotic peptide chain release factor GTP-binding subunit ERF3B, and angiotensinogen (73).…”

Section: Prognostic Biomarkersmentioning

confidence: 99%

Biomarkers in Colorectal Cancer: The Role of Translational Proteomics Research

et al. 2019

View full text Add to dashboard Cite

Colorectal cancer is one of the most common cancers in the world, and it is one of the leading causes of cancer-related death. Despite recent progress in the development of screening programs and in the management of patients with colorectal cancer, there are still many gaps to fill, ranging from the prevention and early diagnosis to the determination of prognosis factors and treatment of metastatic disease, to establish a personalized approach. The genetic profile approach has been increasingly used in the decision-making process, especially in the choice of targeted therapies and in the prediction of drug response, but there are still few validated biomarkers of colorectal cancer for clinical practice. The discovery of non-invasive, sensitive, and specific biomarkers is an urgent need, and translational proteomics play a key role in this process, as they enable better comprehension of colorectal carcinogenesis, identification of potential markers, and subsequent validation. This review provides an overview of recent advances in the search for colorectal cancer biomarkers through proteomics studies according to biomarker function and clinical application.

show abstract

Predicting metachronous liver metastasis from colorectal cancer using serum proteomic fingerprinting

Cited by 13 publications

References 18 publications

Noninvasive urinary protein signatures associated with colorectal cancer diagnosis and metastasis

Noninvasive urinary protein signatures associated with colorectal cancer diagnosis and metastasis

Metastatic Tissue Proteomic Profiling Predicts 5-Year Outcomes in Patients with Colorectal Liver Metastases

Biomarkers in Colorectal Cancer: The Role of Translational Proteomics Research

Contact Info

Product

Resources

About